My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 99

    1.

    Five years' treatment of Parkinson's disease with levodopa. Therapeutic results and survival of 100 patients.

    Sweet RD, McDowell FH.

    Ann Intern Med. 1975 Oct;83(4):456-63.PMID: 1166978 [PubMed - indexed for MEDLINE]Related articles

    2.

    The impact of treatment with levodopa on Parkinson's disease.

    Shaw KM, Lees AJ, Stern GM.

    Q J Med. 1980;49(195):283-93.PMID: 7465763 [PubMed - indexed for MEDLINE]Related articles

    3.

    The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study.

    Bracco F, Battaglia A, Chouza C, Dupont E, Gershanik O, Marti Masso JF, Montastruc JL; PKDS009 Study Group.

    CNS Drugs. 2004;18(11):733-46. Erratum in: CNS Drugs. 2005;19(7):633. PMID: 15330687 [PubMed - indexed for MEDLINE]Related articles

    4.

    Investigation by Parkinson's Disease Research Group of United Kingdom into excess mortality seen with combined levodopa and selegiline treatment in patients with early, mild Parkinson's disease: further results of randomised trial and confidential inquiry.

    Ben-Shlomo Y, Churchyard A, Head J, Hurwitz B, Overstall P, Ockelford J, Lees AJ.

    BMJ. 1998 Apr 18;316(7139):1191-6.PMID: 9583926 [PubMed - indexed for MEDLINE]Related articlesFree article

    5.

    Result of chronic levodopa therapy and its modification by bromocriptine in Parkinson's disease.

    Hoehn MM.

    Acta Neurol Scand. 1985 Feb;71(2):97-106.PMID: 3984685 [PubMed - indexed for MEDLINE]Related articles

    6.

    [Direct switch from conventional levodopa to stalevo (levodopa/carbidopa/entacapone) improves quality of life in Parkinson's disease: results of an open-label clinical study]

    Litvinenko IV, Odinak MM, Mogil'naia VI, Sologub OS, Sakharovskaia AA.

    Zh Nevrol Psikhiatr Im S S Korsakova. 2009;109(1):51-4. Russian. PMID: 19156087 [PubMed - indexed for MEDLINE]Related articles

    7.

    Comparison of dopa decarboxylase inhibitor (carbidopa) combined with levodopa and levodopa alone in Parkinson's disease.

    Lieberman A, Goodgold A, Jonas S, Leibowitz M.

    Neurology. 1975 Oct;25(10):911-6.PMID: 1101099 [PubMed - indexed for MEDLINE]Related articles

    8.

    Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease.

    Krack P, Batir A, Van Blercom N, Chabardes S, Fraix V, Ardouin C, Koudsie A, Limousin PD, Benazzouz A, LeBas JF, Benabid AL, Pollak P.

    N Engl J Med. 2003 Nov 13;349(20):1925-34.PMID: 14614167 [PubMed - indexed for MEDLINE]Related articlesFree article

    9.

    An open-label evaluation of the tolerability and safety of Stalevo (carbidopa, levodopa and entacapone) in Parkinson's disease patients experiencing wearing-off.

    Koller W, Guarnieri M, Hubble J, Rabinowicz AL, Silver D.

    J Neural Transm. 2005 Feb;112(2):221-30. Epub 2004 Oct 22.PMID: 15503197 [PubMed - indexed for MEDLINE]Related articles

    10.

    Does levodopa slow or hasten the rate of progression of Parkinson's disease?

    Fahn S; and the Parkinson Study Group.

    J Neurol. 2005 Oct;252 Suppl 4:IV37-IV42. Review.PMID: 16222436 [PubMed - indexed for MEDLINE]Related articles

    11.

    Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial.

    Holloway RG, Shoulson I, Fahn S, Kieburtz K, Lang A, Marek K, McDermott M, Seibyl J, Weiner W, Musch B, Kamp C, Welsh M, Shinaman A, Pahwa R, Barclay L, Hubble J, LeWitt P, Miyasaki J, Suchowersky O, Stacy M, Russell DS, Ford B, Hammerstad J, Riley D, Standaert D, Wooten F, Factor S, Jankovic J, Atassi F, Kurlan R, Panisset M, Rajput A, Rodnitzky R, Shults C, Petsinger G, Waters C, Pfeiffer R, Biglan K, Borchert L, Montgomery A, Sutherland L, Weeks C, DeAngelis M, Sime E, Wood S, Pantella C, Harrigan M, Fussell B, Dillon S, Alexander-Brown B, Rainey P, Tennis M, Rost-Ruffner E, Brown D, Evans S, Berry D, Hall J, Shirley T, Dobson J, Fontaine D, Pfeiffer B, Brocht A, Bennett S, Daigneault S, Hodgeman K, O'Connell C, Ross T, Richard K, Watts A; Parkinson Study Group.

    Arch Neurol. 2004 Jul;61(7):1044-53. Erratum in: Arch Neurol. 2005 Mar;62(3):430. PMID: 15262734 [PubMed - indexed for MEDLINE]Related articlesFree article

    12.

    Early combination of selegiline and low-dose levodopa as initial symptomatic therapy in Parkinson's disease. Experience in 26 patients receiving combined therapy for 26 months.

    Elizan TS, Moros DA, Yahr MD.

    Arch Neurol. 1991 Jan;48(1):31-4.PMID: 1898848 [PubMed - indexed for MEDLINE]Related articles

    13.

    Comparisons of therapeutic effects of levodopa, levodopa and selegiline, and bromocriptine in patients with early, mild Parkinson's disease: three year interim report. Parkinson's Disease Research Group in the United Kingdom.

    [No authors listed]

    BMJ. 1993 Aug 21;307(6902):469-72.PMID: 8400928 [PubMed - indexed for MEDLINE]Related articlesFree article

    14.

    Treatment of end-of-dose wearing-off in parkinson's disease: stalevo (levodopa/carbidopa/entacapone) and levodopa/DDCI given in combination with Comtess/Comtan (entacapone) provide equivalent improvements in symptom control superior to that of traditional levodopa/DDCI treatment.

    Brooks DJ, Agid Y, Eggert K, Widner H, Ostergaard K, Holopainen A; TC-INIT Study Group.

    Eur Neurol. 2005;53(4):197-202. Epub 2005 Jun 20.PMID: 15970632 [PubMed - indexed for MEDLINE]Related articles

    15.

    Parkinson's disease: progression and mortality.

    Hoehn MM.

    Adv Neurol. 1987;45:457-61.PMID: 3825726 [PubMed - indexed for MEDLINE]Related articles

    16.

    Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses.

    Okereke CS, Kirby L, Kumar D, Cullen EI, Pratt RD, Hahne WA.

    Br J Clin Pharmacol. 2004 Nov;58 Suppl 1:41-9.PMID: 15496222 [PubMed - indexed for MEDLINE]Related articlesFree article

    17.

    Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. Parkinson's Disease Research Group of the United Kingdom.

    Lees AJ.

    BMJ. 1995 Dec 16;311(7020):1602-7.PMID: 8555803 [PubMed - indexed for MEDLINE]Related articlesFree article

    18.

    Bilateral deep brain stimulation in Parkinson's disease: a multicentre study with 4 years follow-up.

    Rodriguez-Oroz MC, Obeso JA, Lang AE, Houeto JL, Pollak P, Rehncrona S, Kulisevsky J, Albanese A, Volkmann J, Hariz MI, Quinn NP, Speelman JD, Guridi J, Zamarbide I, Gironell A, Molet J, Pascual-Sedano B, Pidoux B, Bonnet AM, Agid Y, Xie J, Benabid AL, Lozano AM, Saint-Cyr J, Romito L, Contarino MF, Scerrati M, Fraix V, Van Blercom N.

    Brain. 2005 Oct;128(Pt 10):2240-9. Epub 2005 Jun 23.PMID: 15975946 [PubMed - indexed for MEDLINE]Related articlesFree article

    19.

    Levodopa therapy and survival in idiopathic Parkinson's disease: Olmsted County project.

    Uitti RJ, Ahlskog JE, Maraganore DM, Muenter MD, Atkinson EJ, Cha RH, O'Brien PC.

    Neurology. 1993 Oct;43(10):1918-26.PMID: 8413948 [PubMed - indexed for MEDLINE]Related articles

    20.

    Treatment of Parkinson's disease: problems with a progressing disease.

    Rinne UK.

    J Neural Transm. 1981;51(1-2):161-74.PMID: 7264627 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity